Regencell Bioscience Holdings Limited (RGC) Cash Flow Statement
Where RGC’s cash came from and went, FY2026
June 30, 2026 · U.S. dollars- Cash from operations
- −$7.7M
- Capital expenditures
- $0
- Free cash flow
- −$7.7M
- Returned to shareholders
- $1.8M
- Change in cash
- $11.8M cash at year-end $14.2M
Drawn to scale: where the cash came from and how it was used. Hover for values.
RGC operating cash flow, capex and free cash flow
RGC cash flow trends, FY2017–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | $410.5MFY2017 | −$7.7MFY2026 | — | |
| Capital expenditures | $214.9MFY2017 | $0FY2026 | −100.0% | |
| Free cash flow | $195.6MFY2017 | −$7.7MFY2026 | — | |
| Free cash flow margin | 6.1%FY2017 | 5.0%FY2018 | −1.1 pts | |
| Operating cash flow / net income | 2.41FY2017 | 3.65FY2018 | +1.24 | |
| Stock-based compensation | $8.8MFY2017 | $244,808FY2025 | −36.1%/yr | |
| Dividends paid | $138.9MFY2017 | $138.9MFY2018 | 0.0%/yr | |
| Share buybacks (net) | $228.8MFY2018 | $1.8MFY2026 | −45.5%/yr | |
| Capex / revenue | 6.7%FY2017 | 7.9%FY2018 | +1.2 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
RGC cash flow by activity
RGC net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
RGC cash flow statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$11.7M | −$3.6M | −$4.4M | −$5.9M | −$7.4M | −$1.3M | −$812,371 | −$390,990 | $112.3M | $170.4M |
| Depreciation & amortization | $404,543 | $392,743 | $745,588 | $769,687 | $604,397 | $26,456 | $9,516 | $9,516 | $254.8M | $230.7M |
| Stock-based compensation | — | $244,808 | $449,311 | $930,000 | $2.8M | $0 | $0 | — | $9.2M | $8.8M |
| Change in working capital | $398,805 | $18,858 | −$585,365 | −$508,945 | −$1.0M | $552,978 | $76,282 | $0 | −$35.0M | −$67.4M |
| Other non-cash items | $3.2M | −$185,772 | −$248,000 | −$282,561 | −$159,345 | $0 | $0 | −$9,516 | $68.6M | $68.0M |
| Cash from operating activities | −$7.7M | −$3.1M | −$4.0M | −$5.0M | −$5.3M | −$767,311 | −$726,573 | −$390,990 | $409.9M | $410.5M |
| Investing activities | ||||||||||
| Capital expenditures | $0 | −$152,693 | −$5,376 | −$27,392 | −$780,876 | −$1 | −$117,837 | −$117,837 | −$250.4M | −$214.9M |
| Investments (net) | — | — | $5.2M | $58,978 | −$10.0M | −$10.0M | −$117,837 | −$10.0M | — | — |
| Acquisitions & other investing | $2.5M | $2.8M | $5,376 | $27,392 | $1 | −$780,875 | $117,837 | $10.0M | — | — |
| Cash from investing activities | $2.5M | $2.7M | $5.2M | $58,978 | −$10.8M | −$10.8M | −$117,837 | −$117,837 | — | — |
| Financing activities | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | −$138.9M | −$138.9M |
| Share repurchases & issuance (net) | −$1.8M | — | — | — | — | — | — | — | −$228.8M | — |
| Net borrowing (repayment) | — | — | $0 | $0 | −$431,969 | $612,059 | $988,082 | $480,994 | — | — |
| Shares issued | $0 | $0 | $0 | $0 | $22.7M | $0 | $0 | $0 | $0 | $0 |
| Other financing | $18.7M | — | $102,282 | $134,913 | $164,000 | −$172,314 | $0 | $0 | $350.7M | −$21.1M |
| Cash from financing activities | $16.9M | — | $102,282 | $134,913 | $22.4M | $439,745 | $988,082 | $480,994 | −$17.0M | −$160.0M |
| Summary | ||||||||||
| Net change in cash | $11.8M | −$542,120 | $1.4M | −$4.9M | $6.4M | −$327,566 | $143,672 | $90,004 | −$17.7M | $26.9M |
| Cash at end of period | $14.2M | $2.4M | $3.0M | $1.6M | $6.4M | $59,413 | $386,979 | $243,307 | $228.8M | $246.5M |
| Free cash flow | −$7.7M | −$3.3M | −$4.0M | −$5.0M | −$6.0M | −$767,311 | −$844,410 | −$390,990 | $159.5M | $195.6M |
| Free cash flow margin | — | — | — | — | — | — | — | — | 5.0% | 6.1% |
| Capex / revenue | — | — | — | — | — | — | — | — | 7.9% | 6.7% |
| Operating cash flow / net income | — | — | — | — | — | — | — | — | 3.65 | 2.41 |
| Sep '26 | Mar '26 | Jun '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | Dec '22 | |
|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||
| Net income | −$6.4M | −$5.3M | −$2.2M | −$2.2M | −$1,033 | −$2.9M | −$1,322 | −$2.9M |
| Depreciation & amortization | $363,704 | $40,839 | $159,212 | $372,794 | $769,687 | $384,844 | — | $384,844 |
| Stock-based compensation | — | $1.6M | $224,656 | $224,656 | $100 | $465,000 | $15 | $465,000 |
| Change in working capital | — | — | −$292,682 | −$292,682 | — | −$254,472 | — | −$254,472 |
| Other non-cash items | $916,288 | $1.0M | $89,581 | −$124,001 | $770,635 | −$141,281 | $1,322 | −$141,281 |
| Cash from operating activities | −$5.1M | −$2.6M | −$2.0M | −$2.0M | $1.5M | −$2.5M | $15 | −$2.5M |
| Investing activities | ||||||||
| Capital expenditures | $0 | −$2 | −$2,688 | −$2,688 | $0 | −$13,696 | $0 | −$13,696 |
| Acquisitions & other investing | — | $2.5M | $2.6M | $2.6M | — | $43,185 | — | $43,185 |
| Cash from investing activities | — | $2.5M | $2.6M | $2.6M | — | $29,489 | — | $29,489 |
| Financing activities | ||||||||
| Share repurchases & issuance (net) | −$1.8M | — | — | — | — | — | — | — |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | $18.7M | — | $51,141 | $51,141 | — | $67,457 | — | $67,457 |
| Cash from financing activities | $16.9M | — | $51,141 | $51,141 | — | $67,457 | — | $67,457 |
| Summary | ||||||||
| Net change in cash | $11.8M | −$61,899 | $1.4M | $1.4M | $1.5M | −$4.9M | $15 | −$4.9M |
| Cash at end of period | $14.2M | $2.4M | $3.0M | $3.0M | $1.6M | $1.6M | $15 | $1.6M |
| Free cash flow | −$5.1M | −$2.6M | −$2.0M | −$2.0M | $1.5M | −$2.5M | $15 | −$2.5M |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
RGC cash generation
In fiscal 2026 (ended June 30, 2026), Regencell Bioscience generated -$7.7 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$7.7 million. It returned $1.8 million to shareholders through dividends ($0) and net share buybacks ($1.8 million). Cash and equivalents rose by $11.8 million over the year.
Related: RGC income statement, RGC balance sheet. See the RGC stock overview for the latest quote and news.
RGC cash flow FAQ
What is Regencell Bioscience's free cash flow?
Regencell Bioscience's free cash flow was -$7.7 million in fiscal 2026: -$7.7 million of operating cash flow minus $0 of capital expenditures It was -$3.3 million a year earlier..
How much cash does Regencell Bioscience generate from operations?
Regencell Bioscience generated -$7.7 million of cash from operating activities in fiscal 2026.
How much stock does Regencell Bioscience buy back?
Regencell Bioscience spent $1.8 million on net share repurchases in fiscal 2026.